Back

Preferences for benefit and harm outcomes of GLP-1 receptor agonists in adults with overweight or obesity: a multinational best-worst scaling study

2025-12-16 health economics Title + abstract only
View on medRxiv
Show abstract

AimsWe aimed to elicit preferences for weight and harm outcomes of glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment. We examined heterogeneity across key patient subgroups to support tailored treatment decisions to identify patients most likely to benefit with minimal risks. Material and MethodsWe conducted a best-worst scaling survey of adults with overweight or obesity in 15 European countries, assessing 21 GLP-1 RA outcomesincluding 5% and 10% weight gain (to align with harms) a...

Predicted journal destinations